175 related articles for article (PubMed ID: 12747780)
1. Binding structures and potencies of oxidosqualene cyclase inhibitors with the homologous squalene-hopene cyclase.
Lenhart A; Reinert DJ; Aebi JD; Dehmlow H; Morand OH; Schulz GE
J Med Chem; 2003 May; 46(11):2083-92. PubMed ID: 12747780
[TBL] [Abstract][Full Text] [Related]
2. Umbelliferone aminoalkyl derivatives, a new class of squalene-hopene cyclase inhibitors.
Cravotto G; Balliano G; Tagliapietra S; Palmisano G; Penoni A
Eur J Med Chem; 2004 Nov; 39(11):917-24. PubMed ID: 15501540
[TBL] [Abstract][Full Text] [Related]
3. Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase.
Thoma R; Schulz-Gasch T; D'Arcy B; Benz J; Aebi J; Dehmlow H; Hennig M; Stihle M; Ruf A
Nature; 2004 Nov; 432(7013):118-22. PubMed ID: 15525992
[TBL] [Abstract][Full Text] [Related]
4. The binding site for an inhibitor of squalene:hopene cyclase determined using photoaffinity labeling and molecular modeling.
Dang T; Abe I; Zheng YF; Prestwich GD
Chem Biol; 1999 Jun; 6(6):333-41. PubMed ID: 10375539
[TBL] [Abstract][Full Text] [Related]
5. Photoaffinity labeling of oxidosqualene cyclase and squalene cyclase by a benzophenone-containing inhibitor.
Abe I; Zheng YF; Prestwich GD
Biochemistry; 1998 Apr; 37(17):5779-84. PubMed ID: 9558310
[TBL] [Abstract][Full Text] [Related]
6. The structure of the membrane protein squalene-hopene cyclase at 2.0 A resolution.
Wendt KU; Lenhart A; Schulz GE
J Mol Biol; 1999 Feb; 286(1):175-87. PubMed ID: 9931258
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of a squalene cyclase in complex with the potential anticholesteremic drug Ro48-8071.
Lenhart A; Weihofen WA; Pleschke AE; Schulz GE
Chem Biol; 2002 May; 9(5):639-45. PubMed ID: 12031670
[TBL] [Abstract][Full Text] [Related]
8. Farnesyloxycoumarins, a new class of squalene-hopene cyclase inhibitors.
Cravotto G; Balliano G; Robaldo B; Oliaro-Bosso S; Chimichi S; Boccalini M
Bioorg Med Chem Lett; 2004 Apr; 14(8):1931-4. PubMed ID: 15050630
[TBL] [Abstract][Full Text] [Related]
9. Computational study of the mechanism and the relative free energies of binding of anticholesteremic inhibitors to squalene-hopene cyclase.
Schwab F; van Gunsteren WF; Zagrovic B
Biochemistry; 2008 Mar; 47(9):2945-51. PubMed ID: 18247576
[TBL] [Abstract][Full Text] [Related]
10. 29-Methylidene-2,3-oxidosqualene derivatives as stereospecific mechanism-based inhibitors of liver and yeast oxidosqualene cyclase.
Ceruti M; Rocco F; Viola F; Balliano G; Milla P; Arpicco S; Cattel L
J Med Chem; 1998 Feb; 41(4):540-54. PubMed ID: 9484504
[TBL] [Abstract][Full Text] [Related]
11. Conversion of squalene to the pentacarbocyclic hopene.
Reinert DJ; Balliano G; Schulz GE
Chem Biol; 2004 Jan; 11(1):121-6. PubMed ID: 15113001
[TBL] [Abstract][Full Text] [Related]
12. Inhibition kinetics and affinity labeling of bacterial squalene:hopene cyclase by thia-substituted analogues of 2, 3-oxidosqualene.
Zheng YF; Abe I; Prestwich GD
Biochemistry; 1998 Apr; 37(17):5981-7. PubMed ID: 9558334
[TBL] [Abstract][Full Text] [Related]
13. Structural and stereoelectronic requirements for the inhibition of mammalian 2,3-oxidosqualene cyclase by substituted isoquinoline derivatives.
Barth MM; Binet JL; Thomas DM; de Fornel DC; Samreth S; Schuber FJ; Renaut PP
J Med Chem; 1996 Jun; 39(12):2302-12. PubMed ID: 8691425
[TBL] [Abstract][Full Text] [Related]
14. Quinuclidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase: optimization from lipid profiles.
Brown GR; Hollinshead DM; Stokes ES; Clarke DS; Eakin MA; Foubister AJ; Glossop SC; Griffiths D; Johnson MC; McTaggart F; Mirrlees DJ; Smith GJ; Wood R
J Med Chem; 1999 Apr; 42(7):1306-11. PubMed ID: 10197973
[TBL] [Abstract][Full Text] [Related]
15. Conjugated methyl sulfide and phenyl sulfide derivatives of oxidosqualene as inhibitors of oxidosqualene and squalene-hopene cyclases.
Rocco F; Bosso SO; Viola F; Milla P; Roma G; Grossi G; Ceruti M
Lipids; 2003 Mar; 38(3):201-7. PubMed ID: 12784859
[TBL] [Abstract][Full Text] [Related]
16. Novel squalene-hopene cyclase inhibitors derived from hydroxycoumarins and hydroxyacetophenones.
Cravotto G; Balliano G; Tagliapietra S; Oliaro-Bosso S; Nano GM
Chem Pharm Bull (Tokyo); 2004 Oct; 52(10):1171-4. PubMed ID: 15467228
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity studies of novel orally active non-terpenoic 2,3-oxidosqualene cyclase inhibitors.
Dehmlow H; Aebi JD; Jolidon S; Ji YH; von der Mark EM; Himber J; Morand OH
J Med Chem; 2003 Jul; 46(15):3354-70. PubMed ID: 12852766
[TBL] [Abstract][Full Text] [Related]
18. Novel pyrrole- and 1,2,3-triazole-based 2,3-oxidosqualene cyclase inhibitors.
Watanabe T; Umezawa Y; Takahashi Y; Akamatsu Y
Bioorg Med Chem Lett; 2010 Oct; 20(19):5807-10. PubMed ID: 20728352
[TBL] [Abstract][Full Text] [Related]
19. Crystallization and preliminary X-ray crystallographic analysis of squalene-hopene cyclase from Alicyclobacillus acidocaldarius.
Wendt KU; Feil C; Lenhart A; Poralla K; Schulz GE
Protein Sci; 1997 Mar; 6(3):722-4. PubMed ID: 9070455
[TBL] [Abstract][Full Text] [Related]
20. Vinyl sulfide derivatives of truncated oxidosqualene as selective inhibitors of oxidosqualene and squalene-hopene cyclases.
Ceruti M; Balliano G; Rocco F; Milla P; Arpicco S; Cattel L; Viola F
Lipids; 2001 Jun; 36(6):629-36. PubMed ID: 11485168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
